The HRAS Knockout DLD-1 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal cell population derived from the human DLD-1 colorectal adenocarcinoma cell line. This product features a targeted loss-of-function disruption of the HRAS gene, enabling researchers to investigate HRAS-specific signaling without the confounding presence of clonal selection artifacts. As a polyclonal knockout model, it retains cellular heterogeneity while abrogating HRAS protein expression across the population, offering a robust platform for studying RAS isoform biology in a cancer-relevant background.
The DLD-1 host cell line is an established epithelial model of colorectal carcinoma, characterized by microsatellite instability-high (MSI-H) status and endogenous KRAS mutation. This genetic landscape renders DLD-1 cells particularly dependent on RAS-driven proliferative and survival signaling, making them an ideal context for dissecting the contributions of individual RAS isoforms. The MSI-H phenotype also provides a unique backdrop for evaluating the interplay between DNA mismatch repair deficiency and oncogenic RAS signaling, which is relevant to subsets of colorectal and other solid tumors.
HRAS encodes a small GTPase that functions as a molecular switch downstream of receptor tyrosine kinases such as EGFR, FGFR, and IGF1R. Ligand-bound receptors recruit adaptor Grb2 and guanine nucleotide exchange factor SOS1 to activate HRAS. Active HRAS directly engages RAF kinases (BRAF and CRAF) to propagate the MAPK/ERK cascade, phosphorylating MEK1/2 and ERK1/2, which regulate transcription factors including ELK1, c-Fos, and c-Jun. Simultaneously, HRAS interacts with the p110?? subunit of PI3K, stimulating AKT/mTOR signaling to promote cell growth and survival. Negative regulation is mediated by the GTPase-activating protein NF1. HRAS also couples to RalGDS and RASSF1, linking it to RalA-mediated trafficking and apoptosis.
In the DLD-1 colorectal adenocarcinoma model, HRAS disruption enables examination of KRAS-mutant cancer cell adaptation to loss of parallel RAS isoform signaling. DLD-1 cells harbor an activating KRAS mutation, making this model particularly valuable for investigating functional specialization among HRAS, KRAS, and NRAS in oncogenic maintenance, metastasis, and therapy response. The polyclonal knockout population avoids clonal bias, facilitating study of compensatory rewiring through KRAS or NRAS and evaluation of isoform-selective inhibitors. This model is also relevant to HRAS-mutant cancers (bladder, thyroid, squamous cell carcinoma) and Costello syndrome research, enabling comparative analysis of HRAS-dependent and -independent oncogenic mechanisms.
Researchers can employ the HRAS Knockout DLD-1 Polyclonal Cells in diverse workflows, including RAS isoform specificity studies, colorectal cancer signaling dissection, functional genomics screens, and drug resistance/sensitivity profiling. Typical assays include western blotting for HRAS, p-ERK, and p-AKT; Sanger sequencing and RT-qPCR for genotype/expression verification; colony formation, migration, and apoptosis assays for phenotypic assessment; and phospho-signaling or RNA-seq analysis to map global alterations. For further information, please contact Ascent Research.
